If You Invested $1000 in Veracyte a Decade Ago, This is How Much It'd Be Worth Now

For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.What if you'd invested in Veracyte (VCYT) ten years ago? It may not have been easy to hold on to VCYT for all that time, but if you did, how much would your investment be worth today?Veracyte's Business In-DepthWith that in mind, let's take a look at Veracyte's main business drivers. Headquartered in San Francisco, CA, Veracyte is a global diagnostics company that provides clinicians valuable insights to diagnose and treat cancer. The company has a wide array of advanced genomic tests that leverage deep scientific, clinical and machine learning expertise and other capabilities. Presently, the portfolio includes Afirma (for thyroid cancer), Decipher Prostate (prostate cancer), Prosigna (breast cancer), Envisia (interstitial lung diseases) and Decipher Bladder (bladder cancer), with additional tests in development.These high-performing tests improve diagnostic, prognostic and treatment decisions in cancer and other challenging diseases, helping patients avoid unnecessary procedures and reduce time in finding appropriate treatment.  In the United States, Veracyte offers tests through its central laboratories and makes the tests accessible to patients worldwide by collaborating with local labs. The company recognizes revenues from three sources:Testing revenues (90.4% of total revenues in 2023, up 30.3% from 2022): Upon delivery of the test results, the company bills for testing services considering factors such as payer reimbursement history, contracts and coverage.Product revenues (4.3% of 2023 revenues; up 23.4%):  Includes revenues from Prosigna breast cancer assay, the nCounter Analysis System (acquired from Nanostring Technologies, Inc. in 2019) and related diagnostic kits.Biopharmaceutical and other revenues (5.2% of 2023 revenues; down 43.2%): Includes revenues from licensing or providing access to the company’s assets and services, including testing and contract manufacturing.The company’s 2021 acquisition of Decipher Biosciences expanded its genomic testing menu into urologic cancers and provided Decipher GRID (Genomic Resource for Intelligent Discovery) — a platform and database that helps drive biopharmaceutical partnerships, key opinion leaders (KOL) engagement and pipeline development in urologic cancers.In the same year, Veracyte acquired HalioDx, which enabled it to produce its own in vitro diagnostic (IVD) test kits for use on the nCounter Analysis System. Veracyte intends to migrate the manufacture of the test kits for the nCounter from NanoString to HalioDx.Bottom LineAnyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in Veracyte a decade ago, you're probably feeling pretty good about your investment today.According to our calculations, a $1000 investment made in December 2014 would be worth $5,692.72, or a gain of 469.27%, as of December 11, 2024, and this return excludes dividends but includes price increases.The S&P 500 rose 197.85% and the price of gold increased 111.22% over the same time frame in comparison.Going forward, analysts are expecting more upside for VCYT. Veracyte continues with a robust display of strength in the testing business using its established diagnostic platform. Affirma’s differentiation is leading to market share gains with more people becoming aware of the compelling evidence supporting its quality and performance. The Decipher Prostrate test is also making strides, achieving a ‘Level 1B’ designation in the updated NCCN guidelines. Veracyte’s urology sales force is currently driving Decipher's adoption through awareness and education on the test utility and clinical evidence. Veracyte’s strategic R&D investment in long-term growth driver projects is paying off. Favorable solvency appears encouraging. Meanwhile, the company’s biopharma business faces challenges due to industry-wide spending constraints and less projects. Over the past four weeks, shares have rallied 12.40%, and there have been 3 higher earnings estimate revisions in the past two months for fiscal 2024 compared to none lower. The consensus estimate has moved up as well.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Veracyte, Inc. (VCYT): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks